Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triple Antigen
- Development stage
- Unknown
- Lead developer
- CSL
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Triple Antigen is a combined diphtheria-tetanus-whole cell Bordetella pertussis (DTPw) vaccine developed by Commonwealth Serum Laboratory (CSL). It is designed to provide active immunization against diphtheria, tetanus, and whooping cough (pertussis) by stimulating the immune system to produce protective antibodies against these diseases.
- Brand names
- Triple Antigen
- Other names
- DTPDTPwDTwPTriple Antigen CSL
02
Targets
PRR (Pattern recognition receptors)TCR (CD4+ T-cell receptor)BCR (Host B-cell receptor specific for diphtheria, tetanus, and pertussis epitopes)Diphtheria toxin
Beyond the preview
Go deeper on Triple Antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triple Antigen.